EPIDEMIOLOGICAL CHARACTERISTICS OF PATIENTS WITH NON-SPECIFIC INTERSTITIAL PNEUMONIA IN THE SAMARKAND REGION
Keywords:
interstitial lung disease, nonspecific interstitial pneumonia, epidemiology, age, hospitalizationAbstract
In recent years, there has been a growing interest in the scientific community in the problem of interstitial lung diseases (ILD). The epidemiological characteristics of patients with nonspecific interstitial pneumonia (NSIP), gender and age characteristics remain not fully studied. Data on this issue are available in a limited number of surveys. Purpose of the study: this study will examine the epidemiological features, gender and age characteristics of patients with NSIP in the Samarkand region for the period from 2020 to 2023. Materials and methods: medical records of 262 patients with ILD who were hospitalized at the Samarkand State Medical Center were analyzed association. According to the inclusion and exclusion criteria, a sample of patients with a diagnosis of NSIP was compiled based on a multidisciplinary approach, taking into account the international classification of diseases (ICD-10). Results: the total number of patients was 262, among them 145 (55.3%) men, whose average age was 57.8±13.6 years, 117 (44.7%) women with an average age of 58.9±10.9. Patients with NSIP 190 (72.5%) of the total number of examined patients, men and women 54.7% and 45.3%, respectively. Patients with COVID-19 AP 72(27.5%), men and women 41(56.0%) and 31(43.1%), respectively. The control group included 20 patients: 12 (60%) men and 8 (40%) women. Depending on the severity, each group was divided into subgroups: IA-moderate 125 patients (65.8%), IB-severe 65 patients (34.2%) - NSIP subgroups, IIA-moderate 33 patients (45 .8%) and IIB-severe 39 patients (54.2%) - subgroups of COVID-19, respectively. Our study included patients in the age category from 18 to 90 years. According to the results of our study, the age group of 18-44 years old included 38 (15%), 45-59 years old - 87 (33%), 60-74 years old - 119 (45%) and the older age group 75-90 years old - 18 (7%) patients. Conclusion: Among patients with NSIP, men prevailed 145 (55.3%), the majority (78%) of patients were representatives of older age groups 45-59 (45%) and 60-74 (33%). 158 patients, i.e. 60% are patients with moderate severity of the disease NSIP, in contrast to COVID-19 AP, in which a severe course prevailed.
References
Авдеев С.Н. Идиопатический легочный фиброз: современная концепция и подходы к диагностике. Практическая пульмонология 2014; 4: 16-23.
Анаев Э.Х. Современные представления об идиопатическом легочном фиброзе: в фокусе - биомаркеры. Пульмонология. 2017;27(1):56-64
Авдеев С.Н., Чикина С.Ю., Тюрин И.Е., Белевский А.С., Терпигорев С.А., Ананьева Л.П., Визель А.А., Болдина М.В., Демко И.В., Лещенко И.В., Трофименко И.Н., Киняйкин М.Ф., Степанян И.Э., Зайцева А.С., Петров Д.В. Хронические фиброзирующие интерстициальные заболевания легких с прогрессирующим фиброзным фенотипом: резолюция Междисциплинарного Совета экспертов. Пульмонология. 2021; 31 (4): 505–510. DOI: 10.18093/0869-0189-2021-31-4-505-510
Забозлаев Ф.Г., Кравченко Э.В., Галлямова А.Р., Летуновский Н.Н. Патологическая анатомия легких при новой коронавирусной инфекции (COVID-19). Предварительный анализ аутопсийных исследований. Клиническая практика. 2020;11(2): In Press.doi: 10.17816/ clinpract34849)
Джейкобс Р.Л., Эндрюс К.П.: Гистопатологическая картина гиперчувствительной пневмонии, неспецифической интерстициальной пневмонии/фиброза: исследование диагностики и долгосрочного лечения.Энн Аллергия Астма Иммунол.2003, 90 (2): 265-270. 10.1016/S1081-1206(10)62153-9.
Xu W, Xiao Y, Liu H, Qin M, Zheng W, Shi J. Nonspecific interstitial pneumonia: clinical associations and outcomes. BMC Pulm Med. 2014 Nov 7;14:175. doi: 10.1186/1471-2466-14-175. PMID: 25380997; PMCID: PMC4236489.
Sebastiani M, Faverio P, Manfredi A, Cassone G, Vacchi C, Stainer A, Pozzi MR, Salvarani C, Pesci A, Luppi F. Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential. Biomedicines. 2020 Dec 26; 9(1):17.doi: 10.3390/biomedicines9010017. PMID: 33375368; PMCID: PMC7824155.
Teoh AKY, Corte TJ. Nonspecific Interstitial Pneumonia. Semin Respir Crit Care Med. 2020 Apr; 41(2):184-201.doi: 10.1055/s-0040-1708499. Epub 2020 Apr 12. PMID: 32279290.
Tomassetti S, Ryu JH, Piciucchi S, Chilosi M, Poletti V. Nonspecific Interstitial Pneumonia: What Is the Optimal Approach to Management? Semin Respir Crit Care Med. 2016 Jun; 37(3):378-94.doi: 10.1055/s-0036-1583176. Epub 2016 May 27. PMID: 27231862.
van den Bosch L, Luppi F, Ferrara G, Mura M. Immunomodulatory treatment of interstitial lung disease. Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221117002. doi: 10.1177/17534666221117002. PMID: 35938712; PMCID: PMC9364223.
Lee J, Kim YH, Kang JY, Jegal Y, Park SY; Korean Interstitial Lung Diseases Study Group. Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 3. Idiopathic Nonspecific Interstitial Pneumonia. Tuberc Respir Dis (Seoul). 2019 Oct;82(4):277-284. doi: 10.4046/trd.2018.0092. Epub 2019 May 31. PMID: 31172700; PMCID: PMC6778744.
Taniguchi H, Kondoh Y. Acute and subacute idiopathic interstitial pneumonias. Respirology. 2016 Jul;21(5):810-20. doi: 10.1111/resp.12786. Epub 2016 Apr 28. PMID: 27123874.
Todd NW, Atamas SP, Hines SE, Luzina IG, Shah NG, Britt EJ, Ghio AJ, Galvin JR. Demystifying idiopathic interstitial pneumonia: time for more etiology-focused nomenclature in interstitial lung disease. Expert Rev Respir Med. 2022 Feb;16(2):235-245. doi: 10.1080/17476348.2022.2030710. Epub 2022 Jan 31. PMID: 35034567; PMCID: PMC8983480.
